Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 253,882	$ 568,769
Restricted cash	20,000	20,000
Accounts receivable	19,748	19,748
Prepaid & other current assets	18,394	18,778
Total current assets	312,024	627,295
Intangibles, net of accumulated amortization of $201,180 and $188,339 as of September 30, 2022 and December 31, 2021		821,841
In process R&D	1,101,760	1,101,760
Goodwill	16,182,457	21,062,455
Investment in GMP Bio at fair value	22,640,521
Total assets	40,236,762	23,613,351
Current liabilities:
Accounts payable and accrued liabilities	2,852,159	3,092,723
Accounts payable - related party	349,462	403,423
Contingent consideration	2,625,000	2,625,000
Derivative liability on notes	302,550	340,290
Convertible and short-term debt, net of costs	9,250,021	8,166,622
Convertible debt and short-term debt - related party, net of costs	831,266	826,862
Total current liabilities	16,210,458	15,454,920
Commitments and contingencies (Note 12)
Stockholders’ equity:
Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $.01 par value; 750,000,000 shares authorized; 390,195,433 and 375,288,146 issued and outstanding, respectively	3,901,954	3,752,881
Additional paid-in capital	40,921,704	35,223,842
Accumulated deficit	(20,636,647)	(31,021,050)
Total Oncotelic Therapeutics, Inc. stockholders’ equity	24,187,011	7,955,673
Non-controlling interests	(160,707)	202,758
Total stockholders’ equity	24,026,304	8,158,431
Total liabilities and stockholders’ equity	$ 40,236,762	$ 23,613,351